Evidence map›Paper›PMID 36147867›Full record

ArticleMayo Clinic proceedings. Innovations, quality & outcomes2022

Electrocardiogram-Artificial Intelligence and Immune-Mediated Necrotizing Myopathy: Predicting Left Ventricular Dysfunction and Clinical Outcomes.

Christopher J Klein, Ilke Ozcan, Zachi I Attia, Michal Cohen-Shelly, Amir Lerman, Jose R Medina-Inojosa, Francisco Lopez-Jimenez, Paul A Friedman, Margherita Milone, Shahar Shelly

Open access · goldAbstract read
In one paragraph

Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Deep learning for electrocardiogram interpretation: Bench to bedside.European journal of clinical investigation · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Christopher J KleinDepartment of Neurology, Mayo Clinic, Rochester, MN.
Ilke OzcanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Zachi I AttiaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Michal Cohen-ShellyDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Amir LermanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Jose R Medina-InojosaDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Francisco Lopez-JimenezDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Paul A FriedmanDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Margherita MiloneDepartment of Neurology, Mayo Clinic, Rochester, MN.
Shahar ShellyDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · USSheba Medical Center · ILTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To characterize the utility of an existing electrocardiogram (ECG)-artificial intelligence (AI) algorithm of left ventricular dysfunction (LVD) in immune-mediated necrotizing myopathy (IMNM). Patients and Methods: A retrospective cohort observational study was conducted within our tertiary-care neuromuscular clinic for patients with IMNM meeting European Neuromuscular Centre diagnostic criteria (January 1, 2000, to December 31, 2020). A validated AI algorithm using 12-lead standard ECGs to detect LVD was applied. The output was presented as a percent probability of LVD. Electrocardiograms before and while on immunotherapy were reviewed. The LVD-predicted probability scores were compared with echocardiograms, immunotherapy treatment response, and mortality. Results: The ECG-AI algorithm had acceptable accuracy in LVD prediction in 74% (68 of 89) of patients with IMNM with available echocardiograms (discrimination threshold, 0.74; 95% CI, 0.6-0.87). This translates into a sensitivity of 80.0% and specificity of 62.8% to detect LVD. Best cutoff probability prediction was 7 times more likely to have LVD (odds ratio, 6.75; 95% CI, 2.11-21.51; Conclusion: In IMNM, an AI-ECG algorithm assists detection of LVD, enhancing the decision to advance to echocardiogram testing, while also informing on mortality risk, which is important in the decision of immunotherapy escalation and monitoring.

Indexed as

AI, artificial intelligenceASCVD, atherosclerotic cardiovascular diseaseAUC, area under the curveCK, creatine kinaseCNN, convolutional neural networkECG, electrocardiogramIIM, idiopathic immune-mediated myopathyIMNM, immune-mediated necrotizing myopathyLVD, left ventricular dysfunctionMRI, magnetic resonance imagingOR, odds ratio

Identifiers

PMID36147867
PMCPMC9485848
OpenAlexW4296793402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.